Dotatate ( DrugBank: Dotatate )

4 diseases

41. 巨細胞性動脈炎

臨床試験数 : 128 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03812302 (ClinicalTrials.gov)	September 9, 2019	18/1/2019	Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)	Evaluating the Use of Gallium-68 HA-DOTATATE Positron Emission Tomography/Computerized Tomography (PET/CT) in Patients With Giant Cell Arteritis (GCA.)	Giant Cell Arteritis	Diagnostic Test: 68-Ga HA-DOTATATE PET/CT	University of Alberta	NULL	Recruiting	50 Years	N/A	All	15	Phase 2	Canada

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02019706 (ClinicalTrials.gov)	February 12, 2014	21/12/2013	Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome	Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome	ACTH;Cushing's Syndrome	Radiation: DOTATATE PET-CT;Radiation: F-DOPA PET CT;Radiation: CT scan;Diagnostic Test: Routine MRI scan;Diagnostic Test: Gated MRI scan;Drug: 68Ga-DOTATATE;Drug: 18F-DOPA	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	18 Years	80 Years	All	80	Phase 2	United States

臨床試験数 : 149 / 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03746847 (ClinicalTrials.gov)	December 1, 2018	29/10/2018	PET Imaging in Patients With Suspected Cardiac Sarcoidosis	Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis	Cardiac Sarcoidosis	Drug: Gallium-68 DOTATATE	University of Pennsylvania	Advanced Accelerator Applications	Recruiting	18 Years	N/A	All	20		United States
2	NCT03549598 (ClinicalTrials.gov)	July 20, 2018	25/5/2018	d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis	d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis	Cardiac Sarcoidosis	Drug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scan	Mayo Clinic	NULL	Completed	18 Years	N/A	All	15	Phase 4	United States
3	NCT02812849 (ClinicalTrials.gov)	June 2016	22/6/2016	Somatostatin Receptor Imaging in Cardiac Sarcoidosis	Somatostatin Receptor Imaging in Cardiac Sarcoidosis	Cardiac Sarcoidosis	Drug: Cu-64 DOTATATE	Rigshospitalet, Denmark	NULL	Withdrawn	18 Years	N/A	All	0		Denmark
4	NCT02546388 (ClinicalTrials.gov)	October 2015	9/9/2015	Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis	Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis	Sarcoidosis	Drug: Indium-111 Pentreotide;Drug: Gallium-68 DOTATATE	Marcelo F. Di Carli, MD, FACC	Mallinckrodt	Completed	18 Years	90 Years	All	17	N/A	United States

臨床試験数 : 29 / 薬物数 : 25 - (DrugBank : 11) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03736564 (ClinicalTrials.gov)	January 31, 2019	30/10/2018	Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	Osteomalacia	Combination Product: 68Ga-DOTATATE PET/CT	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	10	Phase 1/Phase 2	United States